Dapagliflozin
- Half-Life (t½)
- PO: 12.9h
- Formula
- C21H25ClO6
- Molecular Weight
- 408.87 g/mol
- Aliases
- Farxiga, Forxiga, BMS-512148
Pharmacological Mechanism
Selective SGLT2 inhibitor — first-in-class (approved EU 2012, US 2014). Mechanism + glucosuric output comparable to empagliflozin; slightly lower SGLT2:SGLT1 selectivity (~1400-fold). DAPA-HF established HFrEF benefit independent of diabetes status; DAPA-CKD established CKD progression reduction.
Half-Life & Elimination Curve (PO: 12.9h)
Plasma (PO)t½ Decay (12.9h)
- 0×t½0h100% (44.3 µg/L)
- 1×t½12.9h50% (22.1 µg/L)
- 2×t½25.8h25% (11.1 µg/L)
- 3×t½38.7h12.5% (5.53 µg/L)
- 4×t½51.6h6.3% (2.77 µg/L)
- 5×t½64.5h3.1% (1.38 µg/L)
Dosing Guidelines
- Oral (PO): Typical 6.67 mg (Range: 5–10 mg)
Pharmacokinetic Parameters
- Oral (PO): Bioavailability (F): 78% · Volume of Distribution (Vd): 112 L · Absorption (ka): 5.12 h⁻¹ (t½ka ≈ 8m) [PMID 22823746]
Pathways It Modulates
Target Organ Systems
- Endocrine System
- digestive
- renal
Interactions
- Empagliflozin (caution): Same class; not combined. Pick one SGLT2i.
- Metformin (synergistic): Standard dual-therapy pairing.
Chemical Structure & Identifiers
- InChIKey: JVHXJTBJCFBINQ-ADAARDCZSA-N
- SMILES: CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)Cl
References